Igaunija -
igauņu -
Ravimiamet
fixopost silmatilgad, lahus
laboratoires thea - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 6ml 1tk; 5mg+50mcg 1ml 2.5ml 1tk
Igaunija -
igauņu -
Ravimiamet
travoprost elvim silmatilgad, lahus
sia elvim - travoprost - silmatilgad, lahus - 40mcg 1ml 2.5ml 1tk
Eiropas Savienība -
igauņu -
EMA (European Medicines Agency)
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmoloogilised vahendid - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Igaunija -
igauņu -
Ravimiamet
stromease silmatilgad, lahus
domes pharma - atsetüültsüsteiin - silmatilgad, lahus - 25mg 1ml 5ml 1tk
Igaunija -
igauņu -
Ravimiamet
bimatoprost/timolol elvim silmatilgad, lahus
sia elvim - timolool+bimatoprost - silmatilgad, lahus - 5mg+0,3mg 1ml 3ml 1tk
Igaunija -
igauņu -
Ravimiamet
travoprost/timolol elvim silmatilgad, lahus
sia elvim - timolool+travoprost - silmatilgad, lahus - 5mg+40mcg 1ml 2.5ml 1tk
Igaunija -
igauņu -
Ravimiamet
opexa silmatilgad, lahus
menarini international operations luxembourg s.a. - bilastiin - silmatilgad, lahus - 6mg 1ml 5ml 1tk
Eiropas Savienība -
igauņu -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Eiropas Savienība -
igauņu -
EMA (European Medicines Agency)
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloogilised vahendid - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
Eiropas Savienība -
igauņu -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).